RT Journal Article SR Electronic T1 Analysis of 200,000 exome-sequenced UK Biobank subjects implicates genes involved in increased and decreased risk of hypertension JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.02.10.21251503 DO 10.1101/2021.02.10.21251503 A1 David Curtis YR 2021 UL http://medrxiv.org/content/early/2021/02/14/2021.02.10.21251503.abstract AB Background Previous analyses have identified common variants along with some specific genes and rare variants which are associated with risk of hypertension but much remains to be discovered.Methods and Results Exome-sequenced UK Biobank participants were phenotyped based on having a diagnosis of hypertension or taking anti-hypertensive medication to produce a sample of 66,123 cases and 134,504 controls. Variants with minor allele frequency (MAF) < 0.01 were subjected to a gene-wise weighted burden analysis, with higher weights assigned to variants which are rarer and/or predicted to have more severe effects. Of 20,384 genes analysed, two genes were exome-wide significant, DNMT3A and FES. Also strongly implicated were GUCY1A1 and GUCY1A1, which code for the subunits of soluble guanylate cyclase. There was further support for the previously reported effects of variants in NPR1 and protective effects of variants in DBH. An inframe deletion in CACNAD10 with MAF = 0.005, rs72556363, is associated with modestly increased of hypertension. Other biologically plausible genes highlighted consist of CSK, AGTR1, ZYX and PREP. All variants implicated were rare and cumulatively they are not predicted to make a large contribution to the population risk of hypertension.Conclusions This approach confirms and clarifies previously reported findings and also offers novel insights into biological processes influencing hypertension risk, potentially facilitating the development of improved therapeutic interventions. This research has been conducted using the UK Biobank Resource.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK Biobank had obtained ethics approval from the North West Multi-centre Research Ethics Committee which covers the UK (approval number: 11/NW/0382) and had obtained informed consent from all participants. The UK Biobank approved an application for use of the data (ID 51119) and ethics approval for the analyses was obtained from the UCL Research Ethics Committee (11527/001).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw data is available on application to UK Biobank. Detailed results with variant counts cannot be made available because they might be used for subject identification. Scripts and relevant derived variables will be deposited in UK Biobank. Software and scripts used to carry out the analyses are also available at https://github.com/davenomiddlenamecurtis.